Collaborative Research Database

We are committed to strengthening collaborations between international, multi-disciplinary clinicians and researchers whose combined expertise will accelerate translational and clinical research into CNS drug delivery.

This database offers opportunities for open dialogue, sharing of resources and collaborative research. Its success depends on the number of researchers represented. Help make this a powerful research tool by submitting your details for inclusion. Thank you.

Please note - by joining this database, you will automatically be added to our mailing list. If at any time you wish to be removed from this mailing list, please email cbtddc@nottingham.ac.uk with the subject line 'Remove from mailing list'.

 

Alexander-Cameron

Alexander, Cameron Professor of Polymer Therapeutics University of Nottingham, UK I am Professor of Polymer Therapeutics at the School of Pharmacy in Nottingham. The main areas of our research are the synthesis and characterisation of bioresponsive materials and externally-activated biosensing and release polymers. These polymers can be triggered to release signals or therapeutic cargoes by heat, light, pH, redox and enzymatic activity. We aim to deliver cancer drugs and / or biological therapeutics to enhance safety, tolerability and efficacy of treatments. Bioresponsive polymers drug delivery biomaterials synthesis

Al-Jamal-Khuloud

Al-Jamal, Khuloud Professor King's College, London, UK I am the chair of Drug Delivery & Nanomedicine in the School of Cancer and Pharmaceutical Sciences at King's College London. I lead a research team focusing on the design and development of novel nanoscale delivery systems specifically for drug, gene, vaccine and radionuclide delivery for therapeutic or diagnostic applications, particularly in the field of cancer studies and brain drug delivery. I have extensive experience with dendrimers, liposomes, quantum dots, polymers, viral vectors, chemically functionalised carbon nanotubes and graphene oxide. I have developed a number of injectable nanocarriers capable of crossing the blood-brain barrier and targeting glioblastoma for cancer therapy in mouse models, and have also designed nanocarriers capable of translocating to the brain after intranasal administration exploiting the nose-to-brain delivery route for treatment of neurodegenerative diseases. nanoscale delivery systems nanotubes

Arvanitis-Costas

Arvanitis, Costas Assistant Professor George W. Woodruff School of Mechanical Engineering, Georgia Institute of Technology, USA I am Head of the Ultrasound Biophysics and Bioengineering Lab. Our research investigates the therapeutic applications of ultrasound with an emphasis on brain cancer, and central nervous system disease and disorders. Our research is focused on understanding the biological effects of ultrasound and acoustically induced microbubble oscillations (acoustic cavitation) and using them to study complex biological systems, such as the neurovascular network and the tumor microenvironment, with the goal of developing novel therapies for the treatment of cancer and central nervous system diseases and disorders.Specific areas of our research include biomedical ultrasonics, linear and nonlinear acoustics, sound propagation in complex media (brain/skull), microbubble dynamics (acoustic cavitation) and control, and image guided therapy. Our lab is particularly active in the field of cancer research, where we conduct fundamental investigations on ultrasound and microbubble-meditated mass transport in brain tumors and develop computational tools to support the more rational design of focused-ultrasound-based treatment of brain cancer. ultrasound biophysics bioengineering focused ultrasound

Battaglia-Giuseppe

Battaglia, Giuseppe Chair of Molecular Bionics; ICREA Professor University College London, UK & Institute of Bioengineering of Catalonia-Barcelona Institute of Science and Technology, Spain I hold the double appointment as Chair of Molecular Bionics in the Department of Chemistry and the institute of Physics of Living Systems at the University College London, and as ICREA Professor and senior group leader at the Institute of Bioengineering of Catalonia part of the Barcelona Institute of Science and Technology. Several of our activities involve the design of novel carriers to target cancer cells and/or cross the blood-brain barrier. We have developed a workflow of activities that allows the design of super-selective nanocarriers, their study in complex in vitro models and finally the pre-clinical validation in relevant models. (See http://www.molecularbionics.org). Nanomedicine blood brain barrier physiology physical biology cancer targeting

Beccaria-Kevin

Beccaria, Kevin Neurosurgeon Hopital Necker - Enfants Malades, Assistance Publique - Hopitaux de Paris, France I am a neurosurgeon specialising in surgical neuro-oncology, working in Necker-Enfants Malades Hospital, Paris, France. I have been working more than 6 years on the ultrasound-induced opening of the blood-brain barrier. I participated in developing an innovative implantable ultrasound device (SonoCloud) allowing for safe and transient opening of the blood-brain barrier with CarThera. This device has been widely assessed in pre-clinical studies and is currently assessed in a human clinical trial (SONOCLOUD). blood brain barrier (BBB) ultrasound SonoCloud

Benzel-Julia

Benzel, Julia PhD student DKFZ, KiTZ Our focus is the analysis of system and CNS drug disposition. I have established cerebral microdialysis in our laboratory in order to investigate unbound drug concentrations in healthy brain or tumour tissue in freely moving animals. We are using PDX and electroporation based models to test BBB/BTB penetration,e.g. in low-/high-grade glioma/ependymoma. These analyses are paired with pharmacokinetic explorations, efficacy and toxicity testing as well as with temptations to improve drug delivery,e.g. through concomitant P-gp-inhibition or packing (liposomes). drug disposition liposomes cerebral microdialysis

Bienemann-Alison

Bienemann, Alison Research Fellow University of Bristol, UK I am currently working as a research fellow for Professor Steven Gill, Functional Neurosurgery research group. My main area of expertise is in the progression of translational research towards the clinical setting, utilising both small and large animals models. CED convection enhanced delivery

Boury-Frank

Boury, Frank Full professor/Vice director Doctoral School Biology Health University of Angers, France Twenty years experience in combination therapeutics including translation of clinical schemes in paediatric populations. Extensive experience as PI and CI of multidisciplinary scientific and training grants in the cancer field. Experience with brain tumour 2D and 3D models and interrogation of chemo- and radio-therapeutics in vivo. Extensive clinical and industrial network in the brain tumour arena. locoregional bioimplants Glioblastoma physico-chemical characterization protein encapsulation

Boyd-Marie

Boyd, Marie Reader in Translation Cancer Research Radiobiology University of Strathclyde, UK Twenty years experience in combination therapeutics including translation of clinical schemes in paediatric populations. Extensive experience as PI and CI of multidisciplinary scientific and training grants in the cancer field. Experience with brain tumour 2D and 3D models and interrogation of chemo- and radio-therapeutics in vivo. Extensive clinical and industrial network in the brain tumour arena. 2D models 3D models chemotherapeutics radiotherapeutics

Bradshaw-Tracey

Bradshaw, Tracey University of Nottingham, UK More than 25 years' experience in the cancer pharmacology and drug discovery fields investigating antitumour activity and mechanisms of action of NCEs, natural products and novel formulations of test agents to enhance and target drug delivery. Of particular interest are self-assembling small molecule hydrogelators and apoferritin-encapsulated formulations for treatment of intractable, drug-resistant cancers. Pharmacology hydrogelators apoferritin-encapsulated formulations

Braz-de-Sousa-Ana-Leticia

Braz de Souza, Ana Leticia University of Nottingham, UK I am working on the development of micro and nanoparticles for brain cancer therapy. microparticles nanoparticles

Brem-Henry

Brem, Henry Professor of Neurosurgery, Ophthalmology, Oncology and Biomedical Engineering Johns Hopkins University, USA I have led a neurosurgical brain tumor research team since 1984, and have extensive PI/CI experience on brain tumor and neuro-oncology grants. My team invented and developed Gliadel® wafers to intraoperatively deliver chemotherapy to brain tumors. This work has been expanded to include local delivery of anti-angiogenic therapies, chemotherapeutic agents and resistance modifiers for primary and metastatic brain tumors. I have worked with collaborators to develop and synthesize new classes of polymers and microchips for drug delivery. Tumor type: rodent brain tumor cell lines, established human glioma lines, primary cell lines derived from patient samples. immunotherapy Gliadel intraoperative chemotherapy microchips polymers rodent brain tumour cell lines established human glioma lines primary cell lines localised drug delivery

Brennan-Paul

Brennan, Paul Senior Clinical Lecturer and Honorary Consultant Neurosurgeon University of Edinburgh, UK As a neurosurgeon specialising in surgical neuro-oncology I have direct experience with carmustine wafers in the treatment of high grade glioma. My clinical work informs my interest in developing novel strategies for delivering chemotherapy focally in management of brain tumours. This led to the collaborations with Dr Unciti-Broceta developing a palladium activated prodrug. I also collaborate with the IMPACT (https://www.impact.eng.ed.ac.uk) team who are developing implantable microsystems for personalised anti-cancer therapy, which complements my interest in localised drug delivery. carmustine wafers palladium Impact

Brunton-Val

Brunton, Val Chair of Cancer Therapeutics University of Edinburgh, UK Use of orthotopic glioblastoma models, including from mice and from fresh patient-derived tumour specimens, to advance the discovery and delivery of novel drug combination therapies for brain cancer. Of particular interest is the use of imaging using a multimodal platform that allows both 2-photon fluorescence and coherent Raman imaging approaches to interrogate the involvement of the brain environment, including blood flow and tissue oxygenation, on tumour behaviour and drug response. adhesion networks tumour microenvironment mouse models fluorescence imaging Raman imaging

Carai-Andrea

Carai, Andrea Chief Bambino Gesù Children's Hospital, Italy Twenty years experience in combination therapeutics including translation of clinical schemes in paediatric populations. Extensive experience as PI and CI of multidisciplinary scientific and training grants in the cancer field. Experience with brain tumour 2D and 3D models and interrogation of chemo- and radio-therapeutics in vivo. Extensive clinical and industrial network in the brain tumour arena. neurosurgery intrathecal therapy

Chaudhary-Neeraj

Chaudhary, Neeraj Principal Investigator Michigan Medicine, USA I am a physician neuroscientist with 15 yr experience in Neurointerventional treatment techniques for neurovascular diseases in adults and children. I perform intra-arterial administration of chemotherapy for retinoblastoma in pediatric age group. I have also treated lacrimal gland ex-pleomorphic adenocystic carcinoma with IA chemotherapy. I am currently working on Objective assessment of bioavailability of IA injected chemotherapy agent in tumor tissue. retinoblastoma neurointervention stroke aneurysm

Choi-James

Choi, James Imperial College, London, UK Noninvasive and localised drug delivery across the blood-brain barrier using ultrasound and microbubbles. I have over 12 journal publications on this topic and continue to develop different aspects of this technology. ultrasound microbubbles

Cima-Michael

Cima, Michael Professor of Engineering Massachusetts Institute of Technology, USA Lead a research lab focusing on developing medical devices for single compartment drug delivery with a history of clinical translation. Currently developing a minimally invasive device for chronic fluid infusion and electrical interfacing with discrete deep-brain structures. Experience as a founder of four startup companies and consulting for several pharmaceutical companies. Medical Devices micropump localized drug delivery neural implant

Cohen-Kenneth

Cohen, Kenneth Professor (Oncology and Pediatrics) Johns Hopkins University, USA Experienced clinical trialist with a particular focus on small scale clinical trial design. Previous and ongoing research related to local drug delivery including the original development of Gliadel® in children and intra-arterial chemotherapy for children with DIPG. Tumor type: All pediatric brain tumors. clinical trial design Gliadel intra-arterial

Dandapani-Madhumita

Dandapani, Madhumita Clinical Associate Professor University of Nottingham, UK I have been a Consultant Paediatric oncologist with clinical expertise in paediatric solid tumours and brain tumours in Nottingham since 2016 and was appointed as Clinical Associate Professor at the University of Nottingham in March 2019. I obtained my PhD in 2012 in cancer cell signalling from the University of Dundee. I have since developed a research niche in tumour metabolism, particularly in childhood brain tumours. I have written clinical trials including PHITT (Paediatric Hepatic International Tumour Trial) and I am co-Investigator on this study. I am a member of the SIOPEL (International Society of Paediatric Oncology Liver group) and on the SIOP Scientific Advisory board for liver tumours. I am the NIHR CRN lead for Paediatric Oncology in the East Midlands and Principal Investigator on several clinical trials. My career aim is to develop novel therapies for children with cancer and to improve outcomes for children with cancer in developing countries. clinical trials amino acid metabolism metabolomics paediatric brain tumour

De-Vleeschouwer-Steven

De Vleeschouwer, Steven Staff neurosurgeon / Professor University Hospitals Leuven, KU Leuven, Belgium Preclinical and conceptual research in nose-to-brain delivery of innovative therapeutics including formulated RNAi substances. Preclinical research in consortium for development of multichannel microcatheter for CED in brain tumors including brainstem locations. nose-to-brain transport tumor micro-environment RNAi CED convection-enhanced delivery intra-nasal intranasal

Ellingson-Benjamin

Ellingson, Benjamin Professor of Radiology and Psychiatry University of California Los Angeles, USA Design, testing and implementation of advanced imaging techniques for quantifying brain tumor biology and response to therapy. radiology Imaging pet MRI

Elliott-Richard

Elliott, Richard Senior Research Fellow CR-UK Edinburgh Centre N/A High Throughput Drug Screening

EntzWerle-Natacha

Entz-Werle, Natacha Professor CHRU Strasbourg - UMR CNRS 7021 unit I have expertise in the study of brain microenvironment with in vitro models combining normal brain cells and patient derived cell lines. Those specific models are important to design drug testing and work on hypoxic brain microenvironment present in normal brain and in tumor itself. My main topic is high grade glioma where hypoxia is playing a major role in blood-brain barrier adaptation and in tumor cell metabolism. drug testing hypoxia cell lines in vitro models

Evans-Stephen

Evans, Stephen University of Leeds, UK Expertise in:1. Developing Therapeutic Microbubbles, as theranostic agents, for enhanced, targeted drug delivery to cancers.2. Nanobubble loaded Liposomes for Drug Delivery microbubbles theranostic agents nanobubbles liposomes

Farrer-Nicola

Farrer, Nicola Synthetic and Analytical Chemist University of Oxford, UK I am a Wellcome Trust Career Re-entry Fellow with a medicinal inorganic chemistry research group in the Department of Chemistry. We design and synthesise novel metal (platinum, gold, lanthanide) compounds and develop selective targeting and delivery strategies (light, ultrasound, liposomal encapsulation, peptide targeting etc.) for applications in the imaging and treatment of cancer. synthetic chemistry Analytical Chemistry metal-based systems drug encapsulation ultrasound

Funjan-Ahmad

Funjan, Ahmad Senior Scientist Ministry of Education, Jordan Advanced Surgical Neurooncology

Gorman-James

Gorman, James Principal Investigator Harvard Wyss Institute, USA Discovery of new transport shuttles for BBB transport and brain delivery. Transport of therapeutics (Abs, proteins, ASOs) and diagnostics into the brain. In vitro and in vivo BBB models. Pre-competitive industry sponsored research consortium for BBB delivery. antibody BBB shuttle BBB transport biologics

Gosselet-Fabien

Gosselet, Fabien Lab Head Artois University, France My Lab uses in vitro blood-brain barrier models to assess and improve CNS drug delivery. We currently use an in vitro model of the human BBB and we are developing BBB models using induced pluripotent stem cells (iPSCs). drug delivery blood-brain barrier models

Green-Adam

Green, Adam Assistant Professor of Pediatrics Children's Hospital, Colorado, USA One of my areas of investigation is systemic chemotherapy penetration to pediatric glioblastoma and DIPG in patient-derived xenograft models and clinical trials. chemotherapy penetration glioblastomas DIPG model

Green-Jordan-J

Green, Jordan J Associate Professor of Biomedical Engineering, Neurosurgery, Oncology, Ophthalmology, Materials Science & Engineering, and Chemical & Biomolecular Engineering Johns Hopkins University, USA My previous and ongoing research focuses on drug, gene and cellular therapies to treat brain tumors. At Johns Hopkins University School of Medicine, I direct the Biomaterials and Drug Delivery Laboratory, serve on the executive committee of the Institute for NanoBioTechnology, and am associate director of the Translational Tissue Engineering Center. I am also Vice Chair of the Drug Delivery Special Interest Group of the Society For Biomaterials. My areas of expertise are: drug delivery systems, biomaterials, nanotechnology, non-viral gene therapy, immunotherapy and cell therapy. Tumor type: All pediatric brain tumors. biomaterials nanotechnology non-viral gene therapy cell therapy immunotherapy stem cells

Grundy-Richard

Grundy, Richard Professor of Neuro-Oncology and Cancer Biology / Co-Director CBTRC University of Nottingham, UK My expertise lies in molecular neuro-oncology, functional imaging, biomarkers, localised drug delivery systems and clinical trials. In particular, I have significant expertise in intraventricular chemotherapy predominantly using etoposide. I am also chief UK investigator for the SIOP ependymoma II trial. Tumour type: Ependymoma, High Grade Glioma, Medulloblastoma. functional imaging biomarkers clinical trials polymers high grade glioma HGG medulloblastoma localised delivery Ependymoma

Hales-Patrick

Hales, Patrick Children with Cancer UK Research Fellow University College London, UK My research area covers advanced MRI techniques for improved diagnosis and monitoring of treatment response in paediatric cancer. I specialize in the development of new imaging techniques for measuring the cellular and vascular structure of paediatric brain tumours. I am currently leading the integration of these techniques into clinical practice at Great Ormond Street Children's Hospital. Using these techniques, we can monitor the blood supply to a tumour, which will have a strong influence on the efficacy of drug delivery. Changes in the tumour microstructure as a response to treatment can also be measured. Magnetic Resonance Imaging diffusion-weighted imaging perfusion-weighted imaging paediatric cancer MRI

Hargrave-Darren

Hargrave, Darren Reader in Paediatric Neuro-Oncology and Consultant Paediatric Neuro-Oncologist University College London, Institute of Child Health / Great Ormond Street Hospital, UK I have expertise in drug development and am an experienced chief investigator in early and late phase clinic trials. I have strong links with pharmaceutical partners and am Chair of the UK Novel Agents subgroup. My collaborations with UCL/GOSH colleagues in drug delivery include: novel nanotechnology- polymersomes, intra-arterial chemotherapy delivery (retinoblastoma) and interest in CED. Tumour type: all paediatric brain tumours. clinical trials nanotechnology polymers intra-arterial delivery convection-enhanced delivery CED

Heravi-Shargh

Heravi Shargh, Vahid Postdoctoral Research Fellow University of Nottingham, UK I am working on a project funded by Children with Cancer UK for convection enhanced delivery of various nanoplatforms of a novel temozolomide analogue (N3-propargyl) in resistant high grade children gliomas. We have developed three distinct nanoconstructs including N3-sulfobutyl ether ß-cyclodextrin (SBE-ß-CD) inclusion nanocomplex, N3-loaded apoferritin nanocage, and N3-SBE-ß-CD-loaded nanoliposomes) and currently evaluating their pharmacokinetic, distribution and efficacy studies in rats. My research focuses on smart nanocarriers to enhance the efficacy and minimize side effects of cancer chemotherapeutics. drug delivery nanocarrier cancer

Howarth-Alison

Howarth, Alison Post-doctoral researcher University of Oxford, UK I recently completed my PhD studying novel and repurposed therapeutics for the treatment of paediatric high grade glioma. My project involved characterising the mechanism of action of Clomipramine, a repurposed therapeutic, including a genome-wide CRISPR-Cas9 screen to determine essential survival genes and identify combinatorial approaches to develop novel therapeutic strategies for paediatric high grade glioma. After completing my PhD, I undertook a short post-doc position in the Department of Chemistry, University of Oxford, studying novel platinum pro-drug formulations for pHGG and DIPG therapies. I am currently working in Alex Bullock's lab in the SGC, University of Oxford where I am studying ALK kinase inhibition as a therapeutic target for DIPG. Previously, I have worked as team leader in the primary pharmacology group (Pfizer, UK) and more recently in the target discovery institute (TDI) high throughput screening group (University of Oxford). paediatric high grade glioma HGG repurposing

Hyare-Harpreet

Hyare, Harpreet Consultant Neuroradiologist and Honorary Clinical Associate Professor UCLH NHS Trust and UCL Institute of Neurology Developing prognostic imaging biomarkers and imaging response to therapy, in both adult and paediatric brain tumours, through translation of novel MRI sequences and advanced image processing techniques. neuroradiology Imaging MRI pet

Itzhaki-Laura

Itzhaki, Laura Professor University of Cambridge, UK My group is developing a new class of protein drugs to intracellular targets for the treatment of cancers (including brain cancers) and neurodegenerative diseases, and hence we need to find methods to deliver these proteins to the brain and into cells. protein drugs

Jackson-Sadhana

Jackson, Sadhana Assistant Clinical Investigator National Institutes of Health, USA I have experience with the use of brain microdialysis, pharmacokinetic analysis, and utilization of preclinical models to study central nervous system (CNS) pharmacology. I lead collaborative preclinical and clinical studies focused on understanding blood-brain barrier integrity in normal brain and malignant gliomas with an effort to develop novel treatment strategies for patients with brain tumors. brain microdialysis neuropharmacology blood-brain barrier malignant glioma

Jamal-Asad

Jamal, Asad Postdoctoral researcher Imperial College London, UK I have been working on understanding the infusion mechanisms in CNS tissue and its microscale mechanical behaviour using experimental techniques. This is important for the optimisation of infusion-based drug delivery therapies such as convection-enhanced delivery. I have recently revealed that drug-infusion in CNS tissue is significantly dependent on the directionality of axons. CNS tissue permeability infusion-based drug delivery microscale mechanics

Janowski-Miroslaw

Janowski, Miroslaw Associate Professor University of Maryland, Baltimore, USA Expertise in intra-arterial drug delivery using MRI and PET guidance. intra-arterial MRI

Jones-Arwyn

Jones, Arwyn Professor of Membrane Traffic and Drug Delivery Cardiff University, Wales, UK I have been developing in vitro assays for analysing transcytosis in murine bEnd3 cells and human brain derived microvascular endothelial cells. This is for monitoring delivery and intracellular traffic of ligands, nanoparticles and antibodies. This was achieved using techniques such as live cell imaging, confocal microscopy and flow cytometry. drug delivery nanoparticles endocytosis cancer cell biology public engagement in science

Katsila-Theodora

Katsila, Theodora Research Assistant Professor/ PI National Hellenic Research Foundation, Greece My research focus spans 3D cancer models, multi-omics and information technologies synergies. The team puts emphasis on translating information growth to knowledge growth and thus, biomarkers represent a key strategy. biomarkers 3D models multi-omics information technology

Khatua-Soumen

Khatua, Soumen Senior Associate Consultant / Director of Pediatric Neuro-Oncology Mayo Clinic, Rochester, USA Clinical trials using loco-regional delivery of biologic agents into the brain, including CARNK and oncolytic viral therapy in DIPG. Our research focus is on optimizing locoregional infusions of drugs into the brain including convection enhanced delivery and nanoparticle technology. logo-regional delivery convection enhanced delivery immunotherapy

Killick-Cole-Clare

Killick-Cole, Clare Post-Doctoral Research Associate University of Bristol, UK I am a post-doctoral research associate with a background in molecular oncology. I've been working for Professor Steven Gill for the past three years. During this time, my focus has been the preclinical analysis of drugs and drug combinations for administration to brain tumours by intermittent convection-enhanced delivery. CED convection-enhanced delivery

Kortylewski-Marcin

Kortylewski, Marcin Associate Professor Beckman Research Institute at City of Hope, USA My group focuses on the development of oligonucleotide-based cancer immunotherapies. We demonstrated the feasibility of using TLR9 agonists, CpG DNA, for targeted delivery of therapeutic STAT3 siRNA or ASO to immune cells infiltrating solid tumors, such as glioma. The first two generations of CpG-STAT3 inhibitors are undergoing safety/tolerability studies assisting IND filing for therapy of human B cell lymphoma and malignant glioma. I am an active member of the Oligonucleotide Therapeutics Society (Advisory Council Member), ASGCT and AACR. oligonucleotide therapeutics Cancer immunotherapy siRNA CpG STAT3 TLR9

Leite-Diana

Leite, Diana Postdoctoral Research Fellow UCL, UK I am a postdoctoral research fellow working on Neuro-Oncological Precision Nanomedicines in the Molecular Bionics lab of Prof Giuseppe Battaglia at UCL: https://www.molecularbionics.org/My previous work at the Brain Tumour Centre, University of Portsmouth, focused on the development of a 3D in vitro model of brain tumours.During an MSc in Biomedical Engineering, I explored the use of polymeric nanoparticles as drug carriers to the bone. Later, as a Research Assistant, I worked with a gene delivery system based on dendrimers for brain regeneration. 3D model polymeric nanoparticles gene delivery dendrimers peptide nanomaterials

Maherally-Zaynah

Maherally, Zaynah Research Fellow University of Portsmouth, UK My current project involves employing a 3D all human 'in vitro' blood brain barrier (BBB) model, recently developed within our laboratories, to assess a range of 'in house' nanoparticles as efficient carriers to facilitate anti-glioma drug across the BBB. In parallel I am also working on investigating a panel of cell cultures derived from breast and lung cancers as well as melanoma with regard to constitutive expression of a number of genes that may be implicated in metastasis to the brain. MODELS nanoparticles

Marlow-Maria

Marlow, Maria Pharmacist University of Nottingham, UK I am a pharmacist with a PhD in drug delivery and over 18 years' experience in the pharmaceutical industry, having worked on many different drug delivery options and formulations including oral, intravenous and inhaled dosage forms. In 2012, I made the transition back to academia.My research is focused on developing drug delivery systems, in collaboration with clinicians that address an unmet clinical need.My current research projects focus on using injectable hydrogels, nanoparticles and microneedles to deliver small molecules, DNA, proteins or peptides for the treatment of cancer (skin, ovarian and brain tumours), HIV and pain. pharmacist self-assembling molecules hydrogel nanocomposites

Mastronuzzi-Angela

Mastronuzzi, Angela Chief Bambino Gesù Children's Hospital, Italy Experience with intrathecal chemotherapy, high dose chemotherapy, CAR-T cells and immunotherapy, target therapy. paediatric brain tumours

May-Jan-Niklas

May, Jan-Niklas PhD student Uniklinik RWTH Aachen - Institute for Experimental Molecular Imaging, Germany Multimodal and multiscale optical imaging to follow nanocarrier translocation across the BBB (in vivo: hybrid CT-FMT, ex vivo: fluorescence, confocal and STED microscopy). Nanomedicine optical imaging

McConville-Chris

McConville, Chris Senior Lecturer University of Birmingham, UK I am a Senior Lecturer in Pharmaceutics, Drug Formulation and Delivery at the University of Birmingham. I have extensive expertise in the design, development and manufacture of both implantable drug delivery devices and nanoparticles. I also have extensive expertise in the solubility enhancement of poorly soluble drugs. I have been involved in the development of a number of drug delivery devices and formulations that have been evaluated in the clinic, one of which is currently in Phase III clinical testing. pharmaceutics drug formulation implantable drug delivery device nanoparticles

McCowage-Geoffrey

McCowage, Geoffrey Paediatric Oncologist Children's Hospital at Westmead, Sydney, Australia Clinical care of children and adolescents with brain tumours. CEO of Australasian Children's Cancer Trials. National PI for BIOMEDE trial. Lab program is with CAR T-cells targeting CNS tumour antigens, potential candidate agent for direct delivery to brain tumours. neuro-oncology CAR T-cells

McGeehan-Rhiannon

McGeehan, Rhiannon Senior Lecturer in Clinical Genetics University of Portsmouth, UK Mitochondrial genome and associated molecular abnormalities (inherited and acquired) could affect the efficacy of drugs that enter the brain. mtDNA

McGuire-Kerry

McGuire, Kerry Undergraduate Student University of Strathclyde, UK Currently undertaking a dissertation on the use of PD-1 inhibitors in paediatric brain tumours.

Meijer-Lisethe

Meijer, Lisethe Consultant Paediatric Oncologist Princess Maxima Centre for Paediatric Oncology, The Netherlands I have worked on the INTREPID study in the CBTRC, looking at drug delivery to leptomeningeal metastasis of (brain) tumours by slow continuous infusion into the CSF through a pump system. intra-CSF neurooncology Paediatrics

Moloney-Cara

Moloney, Cara Research Fellow University of Nottingham, UK Currently developing neurosurgically-applied chemotherapy systems for medulloblastoma and AT/RT tumours. polymer delivery systems

Mullen-Alexander

Mullen, Alexander Professor of Pharmacy Practice University of Strathclyde, UK I am a qualified pharmacist with clinical, industrial and academic experience in drug and delivery device development with an ongoing interest in the treatment of cancers, including those of the central nervous system. My expertise lies in designing injectable/implantable devices that can deliver a variety of drugs and nanoparticles over prolonged periods with a view to minimising the recurrence of cancer from the tumour margins left after standard neurosurgery interventions. These treatments are to synergise with other treatment modalities such as radiotherapy. Tumour type: glioma- and medulloblastoma-derived cell lines. nanoparticles glioma cell lines medulloblastoma cell lines device development polymers formulation Analysis

Mysiorek-Caroline

Mysiorek, Caroline Associate Professor Artois University, France In vitro modelling of the blood-brain barrier and blood-tumor barrier using human cells, to study the BBB properties in a cancer environment and its consequences on the delivery of chemotherapeutic drugs to the brain. blood brain barrier (BBB) in vitro modelling chemoresistance

Needham-David

Needham, David Professor Duke University, NC, USA; and University of Nottingham, UK I lead the Laboratory-to-Clinic Translational Research and Development for Cancer (LCTRDC) resource established in 2018 by a Strategic Development Fund grant from the University of Nottingham. With many anti-cancer drugs not able to be delivered effectively because of their poor water solubility, the so-called "Bricks of the pharmaceutical industry", in a complete paradigm shift, we have created even less-soluble prodrug therapeutics that can form new endogenous-inspired nanoparticle designs for treating brain and other cancers including metastases. The goal of our resource is to bring this unique "Bricks-to-Rocks" technologies from Duke University to Nottingham and engage, across UoN and the Medical School and especially in the CBTRC, basic scientific, pharmaceutical, preclinical and clinical researchers in an effort to bring repurposed and new drugs from bench to bedside. These efforts include: synthesis, characterisation and formulation of a particular new Niclosamide Stearate Pro-drug Therapeutic (NSPT); NSPT testing in vitro for cell-uptake and cytotoxicity in glioblastoma, breast and prostate cancers; and in vivo preclinical studies in brain cancer. The "Bricks-to-Rocks" technology also extends to PET-imageable nanoparticles which, in combination with the NSPTs, form a suite of diagnostic and therapeutic (Diapeutic) "Individualised nano-medicines" for cancer. Prodrug Therapeutics Nano-diagnostics Drug delivery development

Neves-Vera

Neves, Vera Senior Staff Researcher Lisbon University, Portugal I have expertise in blood-brain barrier (BBB) models in vitro and biodistribution in vivo, as well as in the design and synthesis of trans-BBB peptide shuttles. I have also conducted research in collaboration with other groups to test the efficacy of these peptides fused to therapeutic proteins, such as antibodies for Alzheimer's disease. blood-brain barrier peptide shuttles drug delivery systems Nanomedicine BBB MODELS

Oliveira-J.Miguel

Oliveira, J. Miguel Vice-President Institute 3Bs (I3Bs), University of Minho, Portugal Development of dendrimer nanoparticles and multimodal hydrogels for drugs and cells delivery. nanoparticle hydrogel stem cells in vitro models

Ong-Zhan-Yuin

Ong, Zhan Yuin Academic Fellow University of Leeds, UK I am a University Academic Fellow in Health Engineering (Tenure-track), holding a joint appointment between the Schools of Physics and Astronomy and Medicine at the University of Leeds. My research focuses on the design and evaluation of well-defined multifunctional nanomaterials for the targeted delivery of therapeutics in combination with photothermal therapy to address unmet medical needs. nanomaterials photothermal therapy

Pearl-Monica

Pearl, Monica S Associate Professor of Radiology Johns Hopkins University, USA I have extensive clinical and research expertise with catheter-based intra-arterial therapies for adult and pediatric neurovascular disorders of the brain and spine. My neuroradiology background allows for developing complementary neuroimaging platforms to manipulate the blood brain barrier and better define drug distribution. I am PI for two active clinical trials for IA drug delivery (NCT01293539 and NCT01688401) for retinoblastoma and DIPG. Tumor type: DIPG, Retinoblastoma. DIPG retinoblastoma intra-arterial Imaging

Perez-Garcia-Lluisa

Perez-Garcia, Lluisa Anne McLaren Research Fellow University of Nottingham, UK My current interests are mainly in the field of nanobiomedicine, and include the use of metallic and inorganic nanoparticles as well as supramolecular hydrogels for drug delivery of anticancer agents, especially photosensitizers for photodynamic therapy. Also, the bio-functionalization of silicon microparticles to study, individually tag and actuate inside living cells (multiplexing materials). I was appointed as an Anne McLaren Research fellow in September 2017. nanobiomedicine nanoparticles hydrogels photosensitizers

Picco-Vincent

Picco, Vincent Research Associate Centre Scientifique de Monaco, Principality of Monaco We study the capacity of certain anti-angiogenic targeted therapies to permeabilize and pass the BBB. tumour angiogenesis intracellular signalling basic research preclinical research

Pilkington-Geoff

Pilkington, Geoff Professor Emeritus Cellular & Molecular Neuro-oncology Emeritus Professor, University of Portsmouth UK; Honorary Professor, Kings College London UK; & Visiting Professor, Cardiff University UK Development and pre-clinical use of 3D all-human in vitro models of the blood-brain barrier under static and dynamic/flow conditions and appropriate serum, oxygen and basal lamina conditions. brain tumours blood brain barrier

Preat-Veronique

Preat, Veronique Professor Universite Catholique de Louvain, Belgium I lead the group Advanced Drug Delivery and Biomaterials at the University of Louvain. After the definition of an unmet need, a multidisciplinary approach is used to design new drug delivery systems and demonstrate their efficacy and safety in vitro and in vivo. The main area of research is the design, characterisation and preclinical testing of nanomedicines, in particular for glioblastoma treatment. biomaterials Nanomedicine immunotherapy vaccine hydrogel

Rahman-Ruman

Rahman, Ruman Associate Professor of Molecular Neuro-Oncology University of Nottingham, UK My research group has developed a localised drug delivery system in which a biodegradable polymer (PLGA/PEG) is applied around the tumour cavity wall at neurosurgical resection. The polymer forms a paste at room temperature, which solidifies next to the surgical cavity wall at body temperature. This gives spatial control over dose delivery, extending the length of time infiltrative tumour cells are exposed to the drug. My expertise covers: (1) local biomaterial-based drug delivery systems for intracranial tumours, (2) 3D brain tumour models for drug screening, (3) bio-instructive nanotherapeutics, (4) HDAC inhibitors, (5) brain intra-tumour heterogeneity. biomaterials polymers localised drug delivery intraoperative chemotherapy 3D models nanotherapeutics HDAC inhibitors intra-tumour heterogeneity.

Rattray-Zahra

Rattray, Zahra Chancellor's Research Fellow and Lecturer University of Strathclyde, UK I am a Chancellor's Research Fellow and Lecturer at the Strathclyde Institute of Pharmacy and Biomedical Sciences, interested in working at the interface of drug delivery and cancer biology to design drug delivery solutions with improved in vivo performance.Prior to joining Strathclyde in 2018, I was a postdoctoral researcher at the Yale Cancer Centre, where I researched the application of lupus cell-penetrating autoantibodies against glioblastoma.Before this, I was a senior formulation scientist at AstraZeneca where I contributed to tens of drug projects across a diverse molecule portfolio. chemotherapeutics drug delivery biologics cell-penetrating proteins active targeting

Rodriguez-y-Baena-Ferdinando

Rodriguez y Baena, Ferdinando Imperial College, London, UK Since 2016, I have been coordinating a European project on neurosurgical drug delivery for cancer therapy, codenamed EDEN2020 (www.eden2020.eu). This project resulted from a 10-year activity on surgical needle steering, which is currently at the core of the EDEN2020 endeavour. neurosurgical drug delivery EDEN2020 surgical needle steering

Sánchez-Gómez-Pilar

Sánchez-Gómez, Pilar National Health Institute Carlos III, Spain We are experts in the development of preclinical glioma models, working with patient-derived cells as 3D spheres or xenografts, where test the efficiency of different therapeutic drugs. We have characterized the behaviour of these lines in the mouse brain, from the most invasive ones to the most angiogenic and necrotic tumors. We are also very interested in allogenic and immunocompetent models, to analyse the participation of the tumor microenvironment in the response to chemotherapy (both as a physical barrier and as protective cells). Glioblastoma mouse models preclinical assays EGFR tumor microenvironment

Sandberg-David

Sandberg, David Principal Investigator Health Science Center and MD Anderson Cancer Center, University of Texas, USA For over a decade, I have studied local drug delivery into the fourth ventricle of the brain to treat recurrent, malignant posterior fossa tumors in children. I first studied safety and pharmacokinetics in piglets and then non-human primates. These experiments led to a promising pilot trial in humans, and we currently have several open clinical trials for children with recurrent malignant brain tumors originating in the fourth ventricle. local drug delivery Fourth ventricle

Sarmento-Bruno

Sarmento, Bruno Principal Investigator University of Porto, Portugal My research is focused on the development of functionalized nanomedicines for biomedical applications, with particular interest in brain cancer and neurological disorders. I have also specialized in BBB engineering models to validate functionalized nanomedicines and to perform in vitro/in vivo correlation. Nanomedicine targeted drug delivery spheroids BBB models

Schatzlein-Andreas

Schatzlein, Andreas Professor of Translational Therapeutics University College London, UK Drug delivery to the brain is one of our key areas of research and we have published extensively in this area. We have developed a polymer based system that increases drug transport either across the BBB or by nose-to-brain administration. For this reason we have been chosen as partner for example for the EU consortium EPITARGET - to deliver epilepsy medication. The system is being commercially developed by Nanomerics. Nanomedicine

Schmainda-Kathleen

Schmainda, Kathleen Professor Medical College of Wisconsin, USA My team has developed advanced MRI methods to aid in the evaluation of treatment response in patients with brain tumors. While most of our work has been in the adult population, recent work includes pediatric patients. diffusion MRI perfusion MRI

Simpson-Lesley

Simpson, Lesley Consultant RHSC - Edinburgh, UK I have been a paediatric oncology consultant in Edinburgh for almost 7 years. Prior to that, I was a paediatric haematology and oncology consultant in America, where I did all of my medical, paediatric, and specialty training. I participate in CCLG and early phase clinical trials. I have done lab research on AML in the past, but focus exclusively on clinical trials and care of patients currently neuroblastoma lymphoma neurooncology

Sirianni-Rachael

Sirianni, Rachael Professor of Polymer Therapeutics University of Nottingham, UK I lead the Division of Molecular Therapeutics and Formulation at the School of Pharmacy in Nottingham. The main areas of research within Polymer Therapeutics are the synthesis and characterisation of bioresponsive materials and externally-activated biosensing and release polymers. These polymers can be triggered to release signals or therapeutic cargoes by heat, light, pH, redox and enzymatic activity. Bioresponsive polymers drug delivery biomaterials synthesis

Stanyard-Ryan

Stanyard, Ryan Student Keele University, UK Neuroscience student, experience studying pharmacodynamic and pharmacokinetic systems and BBB diffusion elements. Neurology placement - 1 week bespoke tailored programme made by Chair of Medicine of University Hospital of North Midlands.

Straehla-Joelle

Straehla, Joelle Postdoctoral Researcher, Hammond Lab at MIT Boston Children's/Dana-Farber Cancer and Blood Disorders Center, USA I am a pediatric neuro-oncologist in training with a materials science background developing targeted nanocarriers for pediatric brain tumors. My clinical work is at Boston Children's/Dana-Farber and research is under the mentorship of Professor Paula Hammond at MIT's Koch Institute for Integrative Cancer Research. nanoparticle blood brain barrier (BBB) pediatric brain tumor

Tan-Zhengchu

Tan, Zhengchu Research Associate Imperial College London, UK I am developing a brain tissue phantom as a mechanically accurate tool for the in-vitro testing of novel neurosurgical drug delivery tool designs. I am also advancing the application of this high fidelity tissue mimicking material towards surgical training, tissue engineering, mechanobiology and traumatic brain injury studies. brain mimicking material drug diffusion phantom

Thomas-Neil

Thomas, Neil Professor of Medicinal & Biological Chemistry University of Nottingham, UK I am currently Head of the Biological Chemistry Theme within the School of Chemistry and Deputy Director of the Centre for Biomolecular Sciences. My research includes the development of targeted drug delivery vehicles and theranostics based on protein structures and the generation and evaluation of in vivo imaging agents utilizing fluorescence, bioluminescence and MRI modalities. These include quantum dots, BRET and FRET enzyme activated agents, apoferritin and Dps self-assembling nanocages and recombinant spider silk scaffolds. Nanomedicine drug delivery theranostics fluorescence MRI

Topham-Caroline

Topham, Caroline Principal Investigator University of Salford, UK We are interested in understanding how molecular heterogeneity in medulloblastoma may be linked to functional heterogeneity, in terms of sensitivity/resistance to vincristine. Through this work we have identified a potential strategy for sensitization of medulloblastoma lines using a combination treatment, but this second treatment cannot cross the blood-brain barrier. We are therefore interested in making links with researchers with expertise in modes of drug delivery to circumvent this. live cell time-lapse microscopy Cell biology RNA interference

Tyler-Betty

Tyler, Betty Associate Professor Johns Hopkins University School of Medicine, Baltimore, Maryland I work with Dr. Henry Brem in leading the Hunterian Neurosurgical Brain Tumor Laboratory. With the assistance of more than 350 trainees, the laboratory has advanced the understanding of gene therapy, angiogenesis, local and targeted drug delivery, tumor genetics and proteomics, microchip drug delivery, and drug resistance studies in relation to brain tumor therapy. The laboratory has developed many models to address both adult and pediatric CNS pathology including xenograft and syngeneic brain tumor models, as well as primary and metastatic brain and spine tumor models. The laboratory is focused on making a beneficial impact and increasing therapeutic options for patients with brain tumors.

Vaideanu-Alexandra

Vaideanu, Alexandra PhD Student University of Cambridge, UK My PhD focuses on engineering a drug delivery system based on gold nanomaterials for the therapy of glioblastoma multiforme. Synergy between chemo and radiotherapy mediated by gold nanoparticles is further exploited by targeting GBM tumors specifically. We employ amphiphilic peptide sequences which target neuropiln-1 highly expressed in our patient derived cell populations and exploit local delivery by direct injection at the tumor site, using novel Laser-Ablation ICP-MS and MALDI-MS imaging to determine nanoparticle distribution in relation to tumor area. gold nanoparticle glioblastoma multiforme targeting

van-Vuurden-Dannis

van Vuurden, Dannis Paediatric Neuro-Oncologist Prinses Maxima Hospital, Utrecht, The Netherlands I am Chair of the SIOPE DIPG Network and Registry. My expertise lies in preclinical (combinational) drug screens, convection-enhanced delivery and MRI-guided high intensity focal ultrasound (HIFU) in DIPG, BBB-targeted liposomal drug encapsulation, clinical trials in children, and molecular drug imaging (PET imaging of radiolabeled drugs). Tumour type: paediatric high-grade glioma, diffuse midline gliomas / DIPG. preclinical drug screens combinatorial drug screens convection-enhanced delivery MRI-guided high intensity focal ultrasound HIFU DIPG liposomal delivery liposome clinical trials PET imaging high grade glioma HGG CED

Veal-Gareth

Veal, Gareth Professor of Cancer Pharmacology Newcastle University, UK I have expertise in clinical pharmacology, pharmacokinetics and quantification of drug levels in clinical samples (blood, plasma, CSF, tumour material, etc). My research interests lie in the development and validation of assays for the quantification of novel and established anticancer drugs and their metabolites. I am and have been CI on numerous completed and published clinical pharmacology trials. clinical pharmacology pharmacokinetics Ependymoma Assay development pharmacodynamics

Vendrell-Marc

Vendrell, Marc Professor of Translational Chemistry University of Edinburgh, UK Our research group develops chemical agents for photodynamic therapy of glioblastoma. We have invented one of the smallest family of photosensitizers ever reported. These photosensitizers can be coupled to metabolites that can target cancer cells with high selectivity. In collaboration with experts in brain cancer biology and neurosurgery, we are working to translate these new agents for future applications in brain cancer surgery. chemistry Imaging photodynamic therapy

Vivanco-Igor

Vivanco, Igor Team Leader The Institute of Cancer Research, London, UK We are interested in pre-clinical testing of targeted agents with chemistries that enhance BBB penetration. The goal is to establish the level of target engagement for these compounds that is necessary to induce a biological response, and use this information to determine whether this is achievable in patients. We are also, in collaboration with colleagues at the ICR, interested in developing quantitative PD biomarkers of target engagement using non-invasive approaches such as PET. Pharmacology Cancer metabolism Oncogene dependence brain tumours

Walczak-Piotr

Walczak, Piotr Professor, Diagnostic Radiology and Nuclear Medicine University of Maryland, Baltimore, USA My expertise lies in molecular and cellular imaging, and regenerative medicine: (1) Monitoring of drug biodistribution using MRI. (2) Use of stem cells to reduce brain damage caused by chemotherapy. (3) Modeling human brain tumors in animals with intact immune systems. Tumor type: DIPG, Medulloblastoma, GBM. MRI drug biodistribution glial stem cells glial progenitors regenerative medicine intra-arterial DIPG medulloblastoma GBM

Walker-David

Walker, David Paediatric Neuro-Oncologist University of Nottingham, UK I am a Paediatric Neuro-Oncologist with expertise in clinical trials in children's cancers and in intrathecal therapy. Over the past 2 decades whilst treating children with brain tumours and contributing to the design of clinical trials, I concluded that systemically administered drugs have had relatively little impact, particularly in malignant brain tumours. Whilst treating children with leukaemia the outstanding success has been linked to successfully treating the CNS, using intra-CSF therapy and intensified systemic therapies. This experience of CNS targeting has highlighted the need to explore this further in childhood brain tumours. clinical trials intrathecal delivery intra csf drug delivery Paediatric Neuro-oncology

Wang-Julie-Tzu-Wen

Wang, Julie Tzu-Wen Senior Research and Teaching Fellow King's College, London, UK I am currently a senior research and teaching fellow in Nanomedicine in the School of Cancer and Pharmaceutical Sciences at King's College London. The focus of my research is on the pre-clinical translation of nanomedicines for image-guided delivery of drug/gene/radionuclide. Nanomedicine image-guided delivery

Warren-Kathy

Warren, Katherine Senior Investigator National Cancer Institute, USA My research focuses on optimizing clinical trial design by pre-clinically evaluating pharmacokinetics and CNS drug delivery in an animal model. This information is used to determine ideal route of drug delivery (systemic, intrathecal, intranasal, convection-enhanced delivery) to achieve biologically effective dosing at the tumor site. Our animal models have chronically indwelling IV and CSF access, facilitating serial assessment of drug exposures in CSF fluid and the blood compartment simultaneously, allowing for multiple sample collection over time for PK studies. This model has been used to determine CSF and extracellular fluid penetration and toxicities of agents in development for patients with CNS tumors. Tumor type: all children's brain tumors; special focus on brainstem glioma. clinical trial design pharmacokinetics pharmacodynamics preclinical evaluation animal model glioma

Watts-Colin

Watts, Colin Professor University of Birmingham, UK I lead the newly established Brain Cancer Program at the University of Birmingham. My research aims to improve the treatment and survival of patients with glioma by understanding the molecular genetic heterogeneity of individual tumours and using that data to develop novel molecular and functional stratification suitable for application in clinical trials. My clinical practice specializes in neurosurgical oncology with a particular interest in intrinsic gliomas and cerebral metastases. glioma genetic heterogeneity neurosurgery

Wheelhouse-Richard

Wheelhouse, Richard Reader in Medicinal Chemistry University of Bradford, UK Expertise in temozolomide analogues, and in prodrug design, synthesis, activation kinetics and evaluation. temozolomide analogues prodrug design

Willaime-Morawek-Sandrine

Willaime-Morawek, Sandrine Associate Professor in Stem Cells and Neurobiology University of Southampton, UK Expertise on models to study safety and efficacy of drug delivery to the brain, as well as disease models in vitro or in animals. Expertise on neural stem cells and brain tumour stem cells. neural stem cells brain tumour stem cells signalling pathways

Workman-Robert

Workman, Robert Postdoctoral Research Associate University of Nottingham, UK I am a Postdoctoral Research Associate based in the School of Pharmacy, at the University of Nottingham. My expertise is in the use of phage display coupled with next generation sequencing to identify diagnostic peptides. Currently this is being performed to identify peptides that can selectively target glioblastoma for delivery and internalisation phage display diagnostic peptides targeting peptides

Zhan-Wenbo

Zhan, Wenbo Lecturer University of Aberdeen, UK My research in cancer therapy centres on the multiscale modelling of drug delivery to solid tumour. Numerical platforms are established to predict the time-course and spatial-distribution of drug accumulation in different tissue compartments and cell killing. It is coupled with tumour morphological and biological properties extracted from medical images to mimic the intratumoural environment. The output could provide suggestions to the design of drug-delivery-systems, and the strategies of routine chemotherapy and advanced therapies using, i.e. ultrasound and nanoparticles. mathematical modelling drug transport drug delivery systems